PL2939683T3 - Mimetyki apolipoproteiny A-I - Google Patents

Mimetyki apolipoproteiny A-I

Info

Publication number
PL2939683T3
PL2939683T3 PL15157397T PL15157397T PL2939683T3 PL 2939683 T3 PL2939683 T3 PL 2939683T3 PL 15157397 T PL15157397 T PL 15157397T PL 15157397 T PL15157397 T PL 15157397T PL 2939683 T3 PL2939683 T3 PL 2939683T3
Authority
PL
Poland
Prior art keywords
apolipoprotein
mimics
Prior art date
Application number
PL15157397T
Other languages
English (en)
Inventor
Jean-Louis Dasseux
Anna Shenderova Schwendeman
Lingyu Zhu
Original Assignee
Cerenis Therapeutics Holding Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerenis Therapeutics Holding Sa filed Critical Cerenis Therapeutics Holding Sa
Publication of PL2939683T3 publication Critical patent/PL2939683T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
PL15157397T 2009-02-16 2010-02-12 Mimetyki apolipoproteiny A-I PL2939683T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15296209P 2009-02-16 2009-02-16
US15296609P 2009-02-16 2009-02-16
US15296009P 2009-02-16 2009-02-16
EP15157397.9A EP2939683B1 (en) 2009-02-16 2010-02-12 Apolipoprotein A-I Mimics

Publications (1)

Publication Number Publication Date
PL2939683T3 true PL2939683T3 (pl) 2017-07-31

Family

ID=42562076

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15157397T PL2939683T3 (pl) 2009-02-16 2010-02-12 Mimetyki apolipoproteiny A-I
PL10741801T PL2396017T3 (pl) 2009-02-16 2010-02-12 Mimetyki apolipoproteiny A-l

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10741801T PL2396017T3 (pl) 2009-02-16 2010-02-12 Mimetyki apolipoproteiny A-l

Country Status (26)

Country Link
US (4) US8378068B2 (pl)
EP (2) EP2939683B1 (pl)
JP (2) JP5719783B2 (pl)
KR (1) KR101688547B1 (pl)
CN (2) CN104530223A (pl)
AU (1) AU2010213568B2 (pl)
CA (2) CA2982157A1 (pl)
CY (1) CY1118809T1 (pl)
DK (2) DK2396017T3 (pl)
ES (2) ES2554853T3 (pl)
HK (1) HK1209436A1 (pl)
HR (2) HRP20150998T1 (pl)
HU (2) HUE026062T2 (pl)
IL (2) IL214576B (pl)
LT (1) LT2939683T (pl)
MX (3) MX386110B (pl)
NZ (1) NZ594516A (pl)
PH (1) PH12016501912A1 (pl)
PL (2) PL2939683T3 (pl)
PT (2) PT2939683T (pl)
RU (2) RU2532222C2 (pl)
SG (1) SG173624A1 (pl)
SI (2) SI2939683T1 (pl)
SM (2) SMT201700203T1 (pl)
WO (1) WO2010093918A1 (pl)
ZA (1) ZA201105997B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
US20120141576A1 (en) * 2007-03-15 2012-06-07 Benjamin Johnson Treatment of Dermatologic Skin Disorders
WO2008141230A1 (en) 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
US8907061B2 (en) 2008-01-11 2014-12-09 Lawrence Livermore National Security, Llc. Nanolipoprotein particles and related methods and systems for protein capture, solubilization, and/or purification
JP5719783B2 (ja) 2009-02-16 2015-05-20 セレニス セラピューティクス ホールディング エスアー アポリポタンパクａ−ｉ模倣物
ES2648788T3 (es) 2011-01-26 2018-01-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Método para evaluar el riesgo de un sujeto de tener una enfermedad cardiovascular
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
WO2013188879A1 (en) 2012-06-16 2013-12-19 Atherotech, Inc. Measurement of serum lipoproteins
US9239280B2 (en) 2012-06-16 2016-01-19 Atherotech, Inc. Measurement of serum lipoproteins
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2016049061A1 (en) 2014-09-22 2016-03-31 Lawrence Livermore National Security, Llc Electrochemical flow-cell for hydrogen production and nicotinamide co-factor dependent target reduction, and related methods and systems
JP2018516847A (ja) 2015-03-25 2018-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 生体高分子薬を送達するための組成物及び方法
WO2017035326A1 (en) 2015-08-25 2017-03-02 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
WO2017044899A1 (en) * 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
US20190201540A1 (en) * 2016-05-24 2019-07-04 Stc Unm Immunogens, compositions, and methods for treating dyslipidemia
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
US11207422B2 (en) 2017-05-02 2021-12-28 Lawrence Livermore National Security, Llc MOMP telonanoparticles, and related compositions, methods and systems
EP3668600B1 (en) * 2017-08-10 2024-05-15 Abionyx Pharma SA Cargomers
ES2984286T3 (es) * 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
WO2021209808A1 (en) * 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
MX2022012969A (es) 2020-04-16 2022-11-09 Abionyx Pharma Sa Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.
US11752163B2 (en) 2020-04-16 2023-09-12 Abionyx Pharma Sa CER-001 therapy for treating kidney disease
IL301769A (en) 2020-10-01 2023-05-01 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
EP4259280A4 (en) * 2020-12-11 2025-02-12 The Regents Of The University Of Michigan Compositions and methods for preventing, attenuating, and treating medical conditions with shdl nanoparticles
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
CN114940711B (zh) * 2021-10-25 2023-05-12 中山大学 载脂蛋白a-i模拟肽及其应用
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (pl) 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (en) 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
JPS61152632A (ja) 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
JPH0559081A (ja) 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
JPH07507554A (ja) 1992-06-12 1995-08-24 エヌ・ブイ・イノゲネテイクス・エス・エイ 新規ペプチドおよびタンパク質，それらの調製方法，ならびにコレステロール受容体としてのそれらの使用
TW261533B (pl) 1992-07-16 1995-11-01 Kirin Brewery
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
KR100310939B1 (ko) 1992-10-01 2002-06-20 추후제출 태그로암호화한복합조합화학라이브러리
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
DE69943314D1 (de) 1998-02-12 2011-05-12 Kapil N Bhalla Sphingolipid-derivate und verfahren zu deren verwendung
US6410802B1 (en) 1999-04-01 2002-06-25 Esperion Therapeutics, Inc. Methods for synthesizing ether compounds and intermediates therefor
DE60117781T2 (de) * 2000-04-21 2006-11-23 Amgen Inc., Thousand Oaks Peptidderivate des apolipoproteins-a1/aii
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
PL372925A1 (pl) 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Zapobieganie i leczenie nawrotu zwężenia na drodze miejscowego podawania leku
JP2006507223A (ja) 2002-05-17 2006-03-02 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常疾患の治療方法
DE10237571A1 (de) 2002-08-13 2004-02-26 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Endovaskuläres Implantat mit aktiver Beschichtung
CN1839150A (zh) * 2003-07-17 2006-09-27 麦根克斯有限公司 脂肽抗菌衍生物组合物及其应用方法
KR101185609B1 (ko) 2004-07-16 2012-09-24 트러스티즈 오브 터프츠 칼리지 아포리포단백질 ａ１ 미메틱 및 이의 용도
US8206750B2 (en) * 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2007004060A2 (en) 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
TW200744627A (en) 2006-02-21 2007-12-16 Pfizer Prod Inc Methods for the treatment of macular degeneration and related eye conditions
ES2402823T3 (es) 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
WO2008039843A2 (en) 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
WO2008094905A2 (en) 2007-01-29 2008-08-07 Lipid Sciences, Inc. Encapsulated hdl mimetic peptides
US7956035B2 (en) 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
JP2010530433A (ja) 2007-06-20 2010-09-09 メルク・シャープ・エンド・ドーム・コーポレイション Ａｐｏａ−１ペプチド模倣体
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
CA2788223A1 (en) 2009-01-23 2010-07-29 Institut De Cardiologie De Montreal Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
JP5719783B2 (ja) 2009-02-16 2015-05-20 セレニス セラピューティクス ホールディング エスアー アポリポタンパクａ−ｉ模倣物
EP2598158A4 (en) * 2010-07-28 2014-03-12 Inst Cardiologie Montreal Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
EP3842443B1 (en) 2013-03-15 2025-02-19 Cerenis Therapeutics Holding SA Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins

Also Published As

Publication number Publication date
PL2396017T3 (pl) 2015-12-31
MX343654B (es) 2016-11-16
EP2396017A1 (en) 2011-12-21
MX2011008599A (es) 2011-11-18
HRP20150998T1 (hr) 2015-11-20
IL240357A0 (en) 2015-09-24
US20160324923A1 (en) 2016-11-10
SG173624A1 (en) 2011-09-29
PT2396017E (pt) 2015-10-22
US9981008B2 (en) 2018-05-29
LT2939683T (lt) 2017-03-27
JP5719783B2 (ja) 2015-05-20
EP2396017A4 (en) 2013-03-27
CN102395375B (zh) 2015-01-14
RU2532222C2 (ru) 2014-10-27
EP2396017B1 (en) 2015-07-01
AU2010213568A1 (en) 2011-09-01
CN104530223A (zh) 2015-04-22
KR20120004412A (ko) 2012-01-12
CN102395375A (zh) 2012-03-28
HRP20170294T1 (hr) 2017-04-21
IL214576A0 (en) 2011-09-27
ES2620478T3 (es) 2017-06-28
SMT201500318B (it) 2016-02-25
NZ594516A (en) 2012-12-21
RU2011138011A (ru) 2013-03-27
JP2015110677A (ja) 2015-06-18
JP2012518006A (ja) 2012-08-09
SI2396017T1 (sl) 2015-12-31
CA2982157A1 (en) 2010-08-19
ES2554853T3 (es) 2015-12-23
WO2010093918A1 (en) 2010-08-19
HK1165987A1 (en) 2012-10-19
HUE033661T2 (en) 2017-12-28
DK2939683T3 (en) 2017-03-13
PT2939683T (pt) 2017-04-07
CA2752182C (en) 2017-11-28
US9388232B2 (en) 2016-07-12
IL240357A (en) 2017-11-30
DK2396017T3 (en) 2015-09-14
SMT201700203T1 (it) 2017-05-08
IL214576B (en) 2019-05-30
CA2752182A1 (en) 2010-08-19
EP2939683A1 (en) 2015-11-04
EP2939683B1 (en) 2017-01-04
ZA201105997B (en) 2013-10-30
HK1209436A1 (en) 2016-04-01
AU2010213568B2 (en) 2014-11-20
CY1118809T1 (el) 2018-01-10
US20150141330A1 (en) 2015-05-21
US20130231459A1 (en) 2013-09-05
HUE026062T2 (en) 2016-05-30
US20100267631A1 (en) 2010-10-21
PH12016501912A1 (en) 2019-11-18
RU2014134333A (ru) 2016-03-20
SI2939683T1 (sl) 2017-04-26
US8993597B2 (en) 2015-03-31
MX386110B (es) 2025-03-18
KR101688547B1 (ko) 2016-12-21
US8378068B2 (en) 2013-02-19

Similar Documents

Publication Publication Date Title
ZA201105997B (en) Apolipoprotein a-i mimics
IL215035A0 (en) Algae biomass fractionation
IL202079A0 (en) Modular support construction
ZA201201212B (en) Modular support element
EP2501796A4 (en) RECOMBINANT MICROORGANISMS
GB0920754D0 (en) Inamo big book 1
GB0905611D0 (en) Bioreactor
DK2119781T3 (da) Glyceroglycolipidlipase
PL2517095T3 (pl) Obsługiwanie nakładek
PL2261113T3 (pl) Śruba
PL2401325T3 (pl) Stabilizator do zastosowań w artykułach żywnościowych
GB0910420D0 (en) Sureflow float value
GB0906310D0 (en) Culture
GB0906307D0 (en) Culture
GB0906303D0 (en) Culture
GB0906305D0 (en) Culture
GB0906311D0 (en) Culture
GB0906302D0 (en) Culture
GB0906301D0 (en) Culture
GB0906308D0 (en) Culture
GB0906306D0 (en) Culture
GB0906309D0 (en) Culture
GB0906304D0 (en) Culture
GB0915611D0 (en) Ilight
AU328352S (en) Float